Abstract | BACKGROUND: METHOD: Twenty patients with FM diagnosed according to the ACR criteria were treated for 5 days with a 5 mg tropisetron intravenous (i.v.) bolus injection daily. Before the first injection, 3 h later, and before and 3 h after the last injection, the serum levels of substance P were determined. The determination of this substance was carried out by means of an immunoassay from Assay Design Biotrend, Cologne. To evaluate the success of the tropisetron treatment, patients made a global assessment as 'clearly better', 'better', 'unchanged', or 'poor'. Patients who answered 'clearly better' and 'better' were regarded as responders. RESULTS: Of the 20 patients, ten reported a good or very good influence on their pain (responders). In these responders, the means of the serum substance P levels were elevated in comparison with the non-responders, though the difference was not significant. In responders, the 5-HT3 receptor antagonist tropisetron produced a significant decrease in the serum substance P levels, while this did not occur in the non-responders. CONCLUSION: It is possible that the responders to tropisetron represent a subgroup of FM patients for whom substance P and 5-HT3 receptors play key roles in the development of the pain symptoms.
|
Authors | T Stratz, B Fiebich, U Haus, W Müller |
Journal | Scandinavian journal of rheumatology. Supplement
(Scand J Rheumatol Suppl)
Vol. 119
Pg. 41-3
( 2004)
ISSN: 0301-3847 [Print] Norway |
PMID | 15515412
(Publication Type: Journal Article)
|
Chemical References |
- Indoles
- Serotonin 5-HT3 Receptor Antagonists
- Serotonin Antagonists
- Substance P
- Tropisetron
|
Topics |
- Female
- Fibromyalgia
(blood)
- Humans
- Indoles
(pharmacology)
- Middle Aged
- Serotonin 5-HT3 Receptor Antagonists
- Serotonin Antagonists
(pharmacology)
- Substance P
(blood)
- Time Factors
- Tropisetron
|